<p>The advice presented in this article reflects the consensus opinion of research and oncology nurses and a clinical trials practitioner involved in managing patients with metastatic malignant melanoma. The nurses met in September 2011 to discuss the side effects they have encountered when patients are taking vemurafenib and to share best practice on how to manage them. As vemurafenib becomes available in clinics following its recent launch in Europe, nurses will need to anticipate and manage the potential adverse events to ensure patients receive the most effective treatment.</p>